Henry C Marsh

This inventor holds 17 USPTO granted patents and 5 published patent applications, plus 5 CIPO patents and 4 EPO patents. Top assignees: T Cell Sciences, Inc., Celldex Therapeutics Limited, Johns Hopkins University. Active years: 1993-2023.

USPTO Granted Patents = 17 (Patent Applications = 5)

% Patents Active = 88.2

CIPO Patents = 5 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 5.4

ph-index = 9

Forward Citations = 375(Granted Patents)

Company Filing History:

8 out of 24

T Cell Sciences, Inc.

patents

6 out of 45

Celldex Therapeutics Limited

patents

4 out of 3,795

Johns Hopkins University

patents

4. 4 out of 1,424

The Brigham and Women's Hospital, Inc.

patents

5. 3 out of 20

Avant Immunotherapeutics, Inc.

patents

6. 3 out of 158

The University of Mississippi

patents

7. 2 out of 925

University of Iowa Research Foundation

Smithkline Beecham Corporation

patents

where one patent can have more than one assignee

Years Active: 1993-2023

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11541076 - Chimeric antigen receptors targeting TIM-1 (2023-01-03),

2. 11180566 - Antibodies that bind human CD27 and uses thereof (2021-11-23),

3. 9649357 - Treatment of chronic nephropathies using soluble complement receptor type I (sCR1) (2017-05-16),

4. 9295713 - Treatment of chronic nephropathies using soluble complement receptor type I (sCR1) (2016-03-29),

5. 9169325 - Antibodies that bind human CD27 and uses thereof (2015-10-27),

6. 8664176 - Treatment for age-related macular degeneration and other diseases of the eye (2014-03-04),

7. 6316604 - Human C3b/C4b receptor (CR1) (2001-11-13),

8. 6057131 - Preparation and use of sialylated glycoforms of soluble complement (2000-05-02),

9. 5981481 - Human C3b/C4b receptor (CR1) (1999-11-09),

10. 5858969 - Therapeutic methods employing sialylated glycoforms of soluble (1999-01-12),

11. 5856297 - Human C3b/C4b receptor (CR1) (1999-01-05),

12. 5506247 - Compounds that inhibit complement and/or suppress immune activity (1996-04-09),

13. 5472939 - Method of treating complement mediated disorders (1995-12-05),

14. 5456909 - Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) (1995-10-10),

15. 5401767 - Compounds which inhibit complement and/or suppress immune activity (1995-03-28),

Title: The Legacy of Henry C Marsh

Introduction: Henry C Marsh, a distinguished inventor hailing from Reading, MA, has made significant contributions to the field of innovation with his groundbreaking ideas and inventions.

Latest Patents: Henry C Marsh holds several patents in various industries, showcasing his versatility and creativity in inventing new solutions to existing problems.

Career Highlights: Throughout his illustrious career, Henry C Marsh has been recognized for his innovative spirit and dedication to pushing the boundaries of what is possible. His inventions have revolutionized the way we approach everyday challenges.

Collaborations: Henry C Marsh has collaborated with leading experts in the field, fostering a culture of innovation and knowledge-sharing that has led to remarkable advancements in technology and beyond.

Conclusion: Henry C Marsh's impact on the world of inventions and innovations is truly remarkable, and his legacy will continue to inspire future generations of inventors to think outside the box and pursue their creative visions.